Advertisement: TTP Killer 50
5 July, 2018 - 11:03 By Jamie Quested


PhoreMost has grown from a Cambridge University spin-out in 2015 with early proof-of-concept data, to a technically and commercially validated enterprise in 2017.

The Babraham Research Park-based company has developed a next-generation phenotypic screening platform called ‘SITESEEKER’ which it says can identify the best new therapeutic targets for any chosen disease setting and rapidly identify how to develop novel drugs to them.

In May 2018 PhoreMost completed a $15 million Series-A round led by current investors Jonathan Milner, Amadeus Capital Partners, Cambridge Enterprise and cornerstone Parkwalk Advisors. Morningside Ventures, a prolific backer of global biotech enterprises, is the principal new investor.

Newsletter Subscription

Stay informed of the latest news and features